What is known about deferasirox chelation therapy in pediatric HSCT recipients: Two case reports of metabolic acidosis

C. Fucile, F. Mattioli, V. Marini, M. Gregori, A. Sonzogni, A. Martelli, N. Maximova

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	1649-1655
Number of pages	7
Journal	Therapeutics and Clinical Risk Management
Volume	14
DOIs	https://doi.org/10.2147/TCRM.S170761
Publication status	Published - 2018

Cite this

@article{f4dcc66ca11948a5828cb3bf9d69a7fd,

title = "What is known about deferasirox chelation therapy in pediatric HSCT recipients: Two case reports of metabolic acidosis",

author = "C. Fucile and F. Mattioli and V. Marini and M. Gregori and A. Sonzogni and A. Martelli and N. Maximova",

note = "Export Date: 4 February 2019",

year = "2018",

doi = "10.2147/TCRM.S170761",

language = "English",

volume = "14",

pages = "1649--1655",

journal = "Therapeutics and Clinical Risk Management",

issn = "1176-6336",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - What is known about deferasirox chelation therapy in pediatric HSCT recipients: Two case reports of metabolic acidosis

AU - Fucile, C.

AU - Mattioli, F.

AU - Marini, V.

AU - Gregori, M.

AU - Sonzogni, A.

AU - Martelli, A.

AU - Maximova, N.

N1 - Export Date: 4 February 2019

PY - 2018

Y1 - 2018

U2 - 10.2147/TCRM.S170761

DO - 10.2147/TCRM.S170761

M3 - Article

VL - 14

SP - 1649

EP - 1655

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -